eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.
Revision History (1 edits)
DeMerchant - Wednesday, September 20, 2006, 6:21:44am
eFoodSafety.com, provides a proprietary ozonation technology system that cleans and sanitizes equipment and other hard surfaces. The patented technology can also be utilized for direct application on food products. The Company's Ozone Safe Food subsidiary has developed joint relationships with distributors for its ozone equipment, which reduces pathogens and provides longer shelf to fresh produce and meat. The Company's Knock-Out Technologies subsidiary has developed an unique, one-of-a-kind, all-natural and environmentally safe sporicide that eradicates anthrax, as well as the Big Six Germicidal Plus product that adds the elimination of Avian Flu virus to its list of deadly organisms that the germicidal spray can totally kill because of its bacteria-cidal effect.
EFSF eFoodSafety.com, Inc. Subsidiary, Knock-Out Technologies, Ltd.'s Big Six Plus Germicidal Kills Black Mold Business Wire - November 3, 2005 9:30 AM (EDT)
SCOTTSDALE, Ariz., Nov 03, 2005 (BUSINESS WIRE) -- Robert Bowker, President of Knock-Out Technologies, Ltd., a wholly-owned subsidiary of eFoodSafety.com, Inc. (OTCBB: EFSF) announced today that laboratory testing confirmed that the Big Six Germicidal product kills with 100% efficacy "Black Mold," whose clinical name is Stachybotrys chartarum. He pointed out the environmentally safe product's potential usefulness in killing Black Mold in hurricane-devastated areas of the Gulf Coast.
Stachybotrys chartarum, also known as Stachybotrys atra, is a greenish-black mold that can grow on material with a high cellulose and low nitrogen content, such as fiberboard, gypsum board, paper, dust, and lint. Growth occurs when there is moisture from water damage, excessive humidity, water leaks, condensation, water infiltration, or flooding. Constant moisture is required for its growth. (Excerpt from Air Pollution and Respiratory Health Branch, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), http://www.cdc.gov.)
Aerobiology Laboratory Associates, Inc. (http://www.aerobiology.net/), microbiology specialists that assist Indoor Air Quality professionals in all aspects of work-related environmental microbiology, completed the testing at their St. Peters, Missouri laboratory facility and confirmed results that the Big Six Plus Germicidal had a 100% kill rate on Stachybotrys chartarum.
The Big Six Plus Germicidal product, which is non-corrosive, non-carcinogenic and non-toxic, is a "safe" solution to killing Black Mold. It can be used as an environmentally friendly alternative to the typical methods of eradication: commercially available chemical products and bleach solutions. For larger affected areas, professional chemical clean-ups are required in order to clean out and dry the area properly so as to avoid allergic reactions to residual parts of dead mold and recurring mold contamination if there is still a source of moisture.
"The killing of Black Mold by our Big Six Plus Germicidal is a very significant finding since it has been confirmed that after Hurricanes Katrina and Rita, the Gulf Coast has been grossly affected by this type of toxigenic mold. Our environmentally-friendly product would be effective in alleviating the current mold problem in the Gulf Coast," stated Mr. Bowker.
EFSF Knock-Out Technologies, Ltd. Receives First Purchase Order for Sale of Citroxin Cleaner; Citroxin, a shared technology with Big Six Plus Germicidal, to Aid in Hurricane Clean-Up Business Wire - November 30, 2005 8:30 AM (EDT)
SCOTTSDALE, Ariz., Nov 30, 2005 (BUSINESS WIRE) -- eFoodSafety.com, Inc.'s (OTCBB: EFSF) wholly-owned subsidiary Knock-Out Technologies, Ltd. announced today that it has received its first purchase order for its Citroxin Cleaner. It was sold to a contractor involved in restoring the residual damage in the wake of Hurricanes Katrina and Rita in Louisiana. This initial order is specifically being used for clean-up in the Lake Charles, LA area and demonstrates the product's broad spectrum usage and appeal.
The Citroxin Cleaner is an environmentally safe product formulated entirely of food-grade components and a shared technology with Knock-Out Technologies' Big 6 Plus Germicidal formula. Knock-Out Technologies is anxiously awaiting EPA product registration for its Big 6 Germicidal formula which is expected by early February, 2006.
Citroxin Cleaner is being implemented in this clean-up to eradicate black mold since the contractors cannot begin to rebuild the area until the mold is completely killed. Because Citroxin Cleaner is formulated of food-grade components, the residue left from the product will not need to be removed, unlike other cleaners being used to restore the hurricane-damaged areas.
"We anticipate that this initial order will be the first of many because of the myriad of problems currently plaguing the Louisiana, Mississippi, Alabama, Florida and Texas regions," stated Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc. "This clean-up is estimated to continue over the next 3 years and may result in many more sales for Knock-Out Technologies," added Mrs. Gruden.
EFSF Knock-out Technologies' Ingestible Anti-Microbial Formula Kills Candida Species in Independent Laboratory Testing; Human Clinical Studies to Commence Business Wire - January 3, 2006 10:15 AM (EDT)
SCOTTSDALE, Ariz., Jan 03, 2006 (BUSINESS WIRE) -- Robert Bowker, president/CEO of Knock-Out Technologies Ltd., a wholly owned subsidiary of eFoodSafety.com Inc. (OTCBB: EFSF), announced today that its newly developed ingestible food-grade, anti-microbial formula has shown a 100% kill of Candida Species, a major health concern, in independent laboratory testing.
When our body defenses are compromised (immunosuppressed), fungal infections become opportunistic and Candida is the most common of these fungal infections. Candida infections have dramatically increased in the hospital setting, notably the intensive care unit and surgical intensive care unit, with associated morbidity and mortality. The incidence in hospitals increased 500% from 1980 to 1989. Chronically ill patients, such as cancer patients undergoing chemotherapy, steroid dependent transplant patients, HIV positive patients, COPD patients, burn victims and patients with prosthetic implants (valves, joints) are identified as patients at high risk to contract Candida. There is also a high incidence among patients with indwelling catheters and surgical wounds, as well as patients receiving antibiotics or gastric acid-reducing treatments and also patients who suffer from severe trauma, obesity, diabetes, and alcohol or drug abuse. Developing new preventative and treatment strategies has surfaced as a major priority in the medical community. Currently available treatment and prophylaxis is not without risk. A major adverse effect of current therapy is renal toxicity.
Hospital, medical and surgical services now routinely give a prophylactic treatment for their highest risk patients in special care units. The $40,000 increase in the cost of critically ill patients can be attributed to Candida infections. Candida Species in the bloodstream has the highest mortality rate of all pathogens isolated.
Patricia Ross-Gruden, president/CEO of eFoodSafety.com Inc., stated that due to the favorable laboratory results, we are scheduled to begin human clinical studies with our treatment for Candida mid-February 2006. "We feel strongly that we as a company have an obligation to improve outcomes in the treatment of patients with the Candida infection and provide prophylaxis against future Candida infections without the major side effects of currently available treatments. Knock-Out Technologies continues to remain on the cutting edge of revolutionary new products and ideas with which we can improve our lives and do so without causing toxicity to humans," added Ross-Gruden.
eFoodSafety.com, Inc. Subsidiary, Knock-Out Technologies, Ltd. to Conduct Human Clinical Trials Based on Documented Independent Laboratory Results; Human Clinical Studies to Commence Robert Bowker, President/CEO of Knock-Out Technologies, Ltd., a wholly owned subsidiary of eFoodSafety.com, Inc. (OTCBB:EFSF) announced today that Bucks County Clinical Research, Inc. (BCCR) agreed to conduct human clinical trials on Knock-Out Technologies' newly formulated ingestible products after a thorough review of our independent laboratory results and material safety data sheets. This research allows eFoodSafety the ability to document and substantiate our impact on Healthcare in Human subjects.
Bucks County Clinical Research, Inc. (http://bccrinc.com/) is a clinical research facility in its 28th year of performing Human Clinical Studies. This is a fully-licensed FDA approved facility that has successfully completed over 270 clinical trials, and is currently performing 7 clinical trials with major pharmaceutical companies. Some of the major pharmaceutical companies that have conducted their trials with BCCR include GlaxoSmithKline (NYSE: GSK), Pfizer (NYSE: PFE), and Eli-Lilly (NYSE: LLY). Please go to http://bccrinc.com/ for a more complete list. With a population base of over one million to draw from, and a group of 47 physicians and consultants practicing 23 subspecialties, patient visits last year exceeded 150,000. BCCR is well suited to conduct our human clinical trials. Richard M. Goldfarb M.D., FACS, a Director of eFoodSafety.com, Inc. and President of MedElite, Inc., a wholly-owned subsidiary of eFoodSafety.com, Inc., serves as Medical Director of Research & Development at Bucks County Clinical Research, Inc.
Patricia Ross-Gruden, President/CEO of eFoodSafety,com, Inc. stated, "With such an outstanding reputation and experience in performing clinical trials for major pharmaceutical companies, we feel fortunate that our cutting edge products will be studied under the same stringent criteria to which the major pharmaceutical companies must adhere."
Bullish Engulfing pattern formed last two day's signaling a strong Buy signal! Broke key resistence today of .30... Should show up on a lot of peoples stock screener's tonight as a buy... Also possible bird flu possibilities in the works!
EFSF: SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 23, 2006--Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc. (OTCBB:EFSF), announced today that eFoodSafety.com, Inc. has been selected by The KonLin Letter as the .1 Stock Pick for 2006. The KonLin Letter reiterates its "Strong Buy" recommendation of EFSF stock.
According to The KonLin Letter, eFoodSafety.com, Inc. has reorganized itself into a dynamo in less than a quarter, unlike any other low-priced stock followed in all of The KonLin Letter's history.
The KonLin Letter, a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements, does not accept compensation for its analyses of selected companies. The report includes a review of the latest developments of the Company, the Company's market position and potential advantages, along with fundamentals and statistics.
Konrad Kuhn, publisher of The KonLin Letter, cited the following reasons for his 2006 recommendation on EFSF:
-- Avian Influenza formulation for hard and porous surfaces has completed testing with 100% efficacy, while the Avian Influenza ingestible formula will soon undergo human clinical trials on Influenza Virus strains A & B - the Bush Administration in November 2005 proposed a $7.1 Billion budget to combat Avian Influenza in 2006
-- Anthrax Sporicidal is 100% effective on eradicating Anthrax's surrogate organisms, Bacillus Subtilis and Clostridium Sporogenes, on hard and porous surfaces and is expected to receive EPA approval in 2006
-- Cinnergen(TM)'s Direct Response Marketing Campaign is performing well with a National TV campaign underway within a $132 billion diabetes market
-- Citroxin Cleaner was sold to aid and assist the clean-up in Louisiana, specifically to eradicate "black mold" in the Lake Charles, Louisiana area - EPA Registration on this product is anticipated shortly
-- Talsyn(TM) CI/bid Scar Cream's sales are at pace with the Company's initial expectations capturing a share of the $4 billion scar cream market
The KonLin Letter concurs with management that revenue growth should continue through the 3rd quarter ending January 31, 2006, while the 4th quarter ending April 30, 2006 should be when revenue growth begins to hit its stride.
About KonLin Research & Analysis Corp.
The KonLin Letter, http://www.KonLin.com, chooses low-priced stocks to analyze, with an emphasis on emerging growth and special situations poised for explosive price appreciation. The KonLin Letter has constantly been one of the leading publications on Wall Street. It has been rated one of the best performing market letters in the nation, offering a unique service that each month recommends five low-priced selections, including a featured stock of the month. EFSF was the featured stock in the month of September 2005.
About eFoodSafety.com, Inc.
eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.
eFoodSafety.com Inc. Announces Expansion of Marketing Program for Clinically Proven Diabetes/Hypoglycemic Product Thursday December 22, 11:00 am ET Cinnergen(TM) to Begin National Television Advertising Campaign
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Dec. 22, 2005--Patricia Ross-Gruden, president and CEO of eFoodSafety.com Inc. (OTCBB: EFSF - News), announced today that due to the favorable response to the current direct response radio campaign promoting Cinnergen(TM) (www.cinnergen.com), the company will now commence with a national television advertising campaign in order to widen even further the availability of this product formulated to assist the body in metabolizing blood sugar. She further stated that the response and acceptance of this product in this $132 billion market is extremely gratifying in that it is a product widely needed in the diabetes/hypoglycemic market, and is a large step toward profitability for the company.
Cinnergen(TM) is a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar or calories. Cinnergen(TM) is specially formulated to promote healthy glucose metabolism and has been clinically proven to decrease the symptoms that commonly accompany elevated blood sugar and its effects.
Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As a whole food complex, Cinnergen(TM) provides several key ingredients that are generally deficient in a typical American diet and that have been proven clinically through years of research to improve digestion and utilization of sugar to help treat the symptoms of type 2 diabetes, hypoglycemia or insulin resistance.
"We anticipate that the company's third quarter ending Jan. 31, 2006, will begin to reflect sales revenues from our Cinnergen(TM) product, while we further predict double-digit sales revenue increases for the remaining quarters of 2006," added Ross-Gruden.
Dec 23,2005-Cinnergen(TM) is a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar or calories.
23/12/05 Patricia Ross-Gruden, president and CEO of eFoodSafety.com Inc., has announced that due to the favorable response to the current direct response radio campaign promoting Cinnergen(TM) (www.cinnergen.com), the company will now commence with a national television advertising campaign in order to widen even further the availability of this product formulated to assist the body in metabolizing blood sugar. She further stated that the response and acceptance of this product in this $132 billion market is extremely gratifying in that it is a product widely needed in the diabetes/hypoglycemic market, and is a large step toward profitability for the company.
Cinnergen(TM) is a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar or calories. Cinnergen(TM) is specially formulated to promote healthy glucose metabolism and has been clinically proven to decrease the symptoms that commonly accompany elevated blood sugar and its effects.
Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As a whole food complex, Cinnergen(TM) provides several key ingredients that are generally deficient in a typical American diet and that have been proven clinically through years of research to improve digestion and utilization of sugar to help treat the symptoms of type 2 diabetes, hypoglycemia or insulin resistance.
eFoodSafety.com Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a nonprescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous, a weight loss formula focusing on the body's 24-hour metabolic processes.
eFoodSafety.com, Inc.'s Cinnergen Diabetes Product Available for Sale at Major Internet Retailer, Drugstore.com Wednesday January 25, 8:27 am ET
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 25, 2006--Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF - News) announced today that Cinnergen(TM), an all natural liquid nutritional supplement designed to regulate blood sugar, is now available for purchase from Drugstore.com (NASD: DSCM - News; http://www.drugstore.com). ADVERTISEMENT
As a result of our continued Direct Response Marketing Campaign via radio and TV, Drugstore.com, with a total life-to-date customer base of approximately 6.8 million unique customers since inception, has expressed the desire to sell our product. Cinnergen(TM) is a fitting addition to the drugstore.com online store as they currently provide a convenient, private, and informative shopping experience that encourages consumers to buy products essential to healthy everyday living.
Cinnergen(TM) is a patent pending nutritional supplement with 0 calories, 0 grams of fat, 0 carbohydrates, and 0 grams of sugar. Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As the body becomes more efficient with glucose metabolism, overall health is improved.
Drugstore.com, Inc. is a leading online provider of health, beauty, vision and pharmacy solutions through their website http://www.drugstore.com. Drugstore.com, Inc. has three (3) wholly-owned subsidiaries - Beauty.com, Custom Nutrition Services, Inc., and International Vision Direct Corp. Drugstore.com is partners with Amazon.com (NasdaqNM: AMZN - News), CIGNA HealthCare Companies (NYSE: CI - News), General Nutrition Companies, Inc., MSN (NasdaqNM: MSFT - News), PetCareRX, Rite-Aid Corporation (NYSE: RAD - News), to name a few.
"Feedback from our customers has been overwhelmingly positive and Cinnergen(TM) sales continue to escalate rapidly. With Drugstore.com making Cinnergen(TM) readily available, more consumers will be provided the opportunity to purchase Cinnergen(TM) and improve the quality of their life and health," stated Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc.
EFSF eFoodSafety.com, Inc.'s, Cinnergen Diabetes Product to Be Sold at Regional Retail Chain, Richard's Whole Foods Business Wire - January 27, 2006 9:15 AM (EDT)
SCOTTSDALE, Ariz., Jan 27, 2006 (BUSINESS WIRE) -- Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF) announced today that Cinnergen(TM), an all natural liquid nutritional supplement designed to regulate blood sugar, is now available for purchase at any of the Richard's Whole Foods locations, as well as their educational internet site http://www.richardswholefoods.com.
Richard's Whole Foods specializes in bringing to its patrons the highest quality natural foods, supplements, and bulk foods at the lowest possible prices. Richard's Whole Foods' interest to carry Cinnergen(TM) was as a result of the overwhelming request from its patrons resulting directly from our continued Radio and TV Direct Response Marketing Campaign. Richard's Whole Foods has 10 store locations in the Sarasota, FL area.
Cinnergen(TM) is a patent pending nutritional supplement with 0 calories, 0 grams of fat, 0 carbohydrates, and 0 grams of sugar. Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As the body becomes more efficient with glucose metabolism, overall health is improved.
"Richard's Whole Foods is a quality establishment that caters to a clientele already looking for solutions to better health and wellness - both of which they will find in our product Cinnergen(TM)," stated Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc.
About Cinnergen(TM)
Cinnergen(TM) (www.cinnergen.com) is a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar, or calories. Cinnergen(TM) is specially formulated to promote healthy glucose metabolism and to decrease the symptoms that commonly accompany elevated blood sugar and its effects. Cinnergen(TM) delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. As a whole food complex, Cinnergen(TM) provides several key ingredients that have been proven clinically through years of research to improve digestion and utilization of sugar, which are generally deficient in a typical American diet.
About eFoodSafety.com, Inc.
eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.
Logged
